First test: how a new drug behaves in damaged livers
NCT ID NCT05891158
Summary
This early-stage study aimed to understand how the body processes a single dose of the experimental drug fazirsiran in people with varying levels of liver damage, compared to people with normal liver function. It involved 34 adults, some with liver scarring (cirrhosis) and some without. The main goal was to measure drug levels in the blood and check for safety over a 6-month follow-up period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRU Hungary Kft
Kistarcsa, 2143, Hungary
-
Summit Clinical Research s.r.o.
Bratislava, 851 05, Slovakia
-
Summit Clinical Research s.r.o.
Malacky, Slovakia
-
Summit Clinical Research s.r.o.
Nové Zámky, 940 34, Slovakia
Conditions
Explore the condition pages connected to this study.